Jeffrey S. Parkin

Array ( [id] => 13635279 [patent_doc_number] => 09844589 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-12-19 [patent_title] => Modified human immunodeficiency virus type 1 (HIV-1) group M consensus envelope glycoproteins capable of inducing broadly reactive T- and B-cell responses [patent_app_type] => utility [patent_app_number] => 13/137517 [patent_app_country] => US [patent_app_date] => 2011-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 178 [patent_figures_cnt] => 301 [patent_no_of_words] => 19199 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13137517 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7656824 [patent_doc_number] => 20110306093 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-12-15 [patent_title] => 'INTERGENIC REGIONS AS NOVEL SITES FOR INSERTION OF HIV DNA SEQUENCES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA' [patent_app_type] => utility [patent_app_number] => 13/209539 [patent_app_country] => US [patent_app_date] => 2011-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 19129 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0306/20110306093.pdf [firstpage_image] =>[orig_patent_app_number] => 13209539 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8883606 [patent_doc_number] => 20130156791 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-06-20 [patent_title] => 'METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HIV-1 INFECTIONS' [patent_app_type] => utility [patent_app_number] => 13/814954 [patent_app_country] => US [patent_app_date] => 2011-08-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 18545 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13814954 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7817491 [patent_doc_number] => 20120064111 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-03-15 [patent_title] => 'ATTENUATED VACCINES FOR NON-SEGMENTED NEGATIVE SENSE RNA VIRUSES' [patent_app_type] => utility [patent_app_number] => 13/183232 [patent_app_country] => US [patent_app_date] => 2011-07-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 14386 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0064/20120064111.pdf [firstpage_image] =>[orig_patent_app_number] => 13183232 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7754693 [patent_doc_number] => 20120027798 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-02-02 [patent_title] => 'ANTIBODY GENE TRANSFER AND RECOMBINANT AAV THEREFOR' [patent_app_type] => utility [patent_app_number] => 13/177338 [patent_app_country] => US [patent_app_date] => 2011-07-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 10093 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0027/20120027798.pdf [firstpage_image] =>[orig_patent_app_number] => 13177338 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8779642 [patent_doc_number] => 20130101617 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-04-25 [patent_title] => 'ENV TRIMER IMMUNOGENS' [patent_app_type] => utility [patent_app_number] => 13/805637 [patent_app_country] => US [patent_app_date] => 2011-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 25313 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13805637 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7561313 [patent_doc_number] => 20110275146 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-11-10 [patent_title] => 'FUSION PROTEINS COMPRISING DP-178 AND OTHER VIRAL FUSION INHIBITOR PEPTIDES USEFUL FOR TREATING AIDS' [patent_app_type] => utility [patent_app_number] => 13/161919 [patent_app_country] => US [patent_app_date] => 2011-06-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 83 [patent_figures_cnt] => 83 [patent_no_of_words] => 32982 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 10 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0275/20110275146.pdf [firstpage_image] =>[orig_patent_app_number] => 13161919 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8096025 [patent_doc_number] => 20120083587 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-04-05 [patent_title] => 'BIOLOGICALLY ACTIVE POLYPEPTIDES DERIVED FROM A NOVEL EARLY STAGE PREGNANCY FACTOR DESIGNATED MATERNIN (MA)' [patent_app_type] => utility [patent_app_number] => 13/159285 [patent_app_country] => US [patent_app_date] => 2011-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 57 [patent_figures_cnt] => 57 [patent_no_of_words] => 57475 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0083/20120083587.pdf [firstpage_image] =>[orig_patent_app_number] => 13159285 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9174342 [patent_doc_number] => 20130316326 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-11-28 [patent_title] => 'ANIMAL MODEL FOR THE EVALUATION OF THE EFFICACY OF AN HIV VACCINE' [patent_app_type] => utility [patent_app_number] => 13/818890 [patent_app_country] => US [patent_app_date] => 2011-06-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 53 [patent_figures_cnt] => 53 [patent_no_of_words] => 28858 [patent_no_of_claims] => 34 [patent_no_of_ind_claims] => 19 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13818890 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7484543 [patent_doc_number] => 20110250220 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-10-13 [patent_title] => 'MODIFIED GP140 ENVELOPE POLYPEPTIDES OF HIV-1 ISOLATES, COMPOSITIONS, STABILIZED TRIMERIC COMPLEXES, AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/100941 [patent_app_country] => US [patent_app_date] => 2011-05-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 29 [patent_figures_cnt] => 29 [patent_no_of_words] => 55304 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 6 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0250/20110250220.pdf [firstpage_image] =>[orig_patent_app_number] => 13100941 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 5936072 [patent_doc_number] => 20110212164 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-09-01 [patent_title] => 'POLYNUCLEOTIDES ENCODING ANTIGENIC HIV TYPE C POLYPEPTIDES, POLYPEPTIDES AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 13/099219 [patent_app_country] => US [patent_app_date] => 2011-05-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 30795 [patent_no_of_claims] => 52 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0212/20110212164.pdf [firstpage_image] =>[orig_patent_app_number] => 13099219 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7652059 [patent_doc_number] => 20110301328 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-12-08 [patent_title] => 'POLYVALENT VACCINE' [patent_app_type] => utility [patent_app_number] => 13/094734 [patent_app_country] => US [patent_app_date] => 2011-04-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 109 [patent_figures_cnt] => 109 [patent_no_of_words] => 13253 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0301/20110301328.pdf [firstpage_image] =>[orig_patent_app_number] => 13094734 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8977613 [patent_doc_number] => 20130211043 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-08-15 [patent_title] => 'METHOD FOR PREVENTING HIV-1 INFECTION OF CD4+ CELLS' [patent_app_type] => utility [patent_app_number] => 13/093331 [patent_app_country] => US [patent_app_date] => 2011-04-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 12003 [patent_no_of_claims] => 2 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13093331 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11342390 [patent_doc_number] => 09526777 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-12-27 [patent_title] => 'Methods for the induction of ebola virus-specific immune responses comprising administering a replication-defective chimpanzee adenovirus vector expressing the ebola virus glycoprotein' [patent_app_type] => utility [patent_app_number] => 13/641655 [patent_app_country] => US [patent_app_date] => 2011-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 28 [patent_no_of_words] => 10300 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13641655 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7656393 [patent_doc_number] => 20110305662 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2011-12-15 [patent_title] => 'METHODS OF TREATING IMMUNODEFICIENCY VIRUS INFECTION' [patent_app_type] => utility [patent_app_number] => 13/088136 [patent_app_country] => US [patent_app_date] => 2011-04-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 18570 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0305/20110305662.pdf [firstpage_image] =>[orig_patent_app_number] => 13088136 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8617307 [patent_doc_number] => 20130022619 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-01-24 [patent_title] => 'METHODS AND COMPOSITIONS FOR INHIBITING HIV TRANSMISSION' [patent_app_type] => utility [patent_app_number] => 13/639831 [patent_app_country] => US [patent_app_date] => 2011-04-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 6 [patent_no_of_words] => 15223 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13639831 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8041503 [patent_doc_number] => 20120070488 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-03-22 [patent_title] => 'METHOD OF INDUCING NEUTRALIZING ANTIBODIES TO HUMAN IMMUNODEFICIENCY VIRUS' [patent_app_type] => utility [patent_app_number] => 13/083466 [patent_app_country] => US [patent_app_date] => 2011-04-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 31 [patent_no_of_words] => 12876 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0070/20120070488.pdf [firstpage_image] =>[orig_patent_app_number] => 13083466 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 7818751 [patent_doc_number] => 20120065371 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-03-15 [patent_title] => 'Recombinant proteins from filoviruses and their use' [patent_app_type] => utility [patent_app_number] => 13/066047 [patent_app_country] => US [patent_app_date] => 2011-04-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 7 [patent_figures_cnt] => 7 [patent_no_of_words] => 19862 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] => publications/A1/0065/20120065371.pdf [firstpage_image] =>[orig_patent_app_number] => 13066047 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8300976 [patent_doc_number] => 20120183533 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2012-07-19 [patent_title] => 'MIMOTOPES OF HIV ENV' [patent_app_type] => utility [patent_app_number] => 13/075761 [patent_app_country] => US [patent_app_date] => 2011-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 27322 [patent_no_of_claims] => 53 [patent_no_of_ind_claims] => 23 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13075761 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8637105 [patent_doc_number] => 20130028908 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-01-31 [patent_title] => 'MONOCLONAL ANTIBODIES DIRECTED AGAINST HIV p17 PROTEIN' [patent_app_type] => utility [patent_app_number] => 13/637997 [patent_app_country] => US [patent_app_date] => 2011-03-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 3678 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13637997 [rel_patent_id] =>[rel_patent_doc_number] =>)